Moderna Inc. (MRNA) announced Friday afternoon that the latest study of its potential COVID-19 vaccine has begun. The first participants in each age range have been dosed with its vaccine candidate, known as mRNA-1273, and will receive another dose 28 days later before being followed for 12 months to determine efficacy. The company intends to enroll 600 patients in the study across two age groups, 18 to 55 and older than 55. Moderna previously released limited details about its phase 1 trial of the vaccine, saying that it produced necessary antibodies in some subjects ( ) but neglecting to provide full datasets ( ). Moderna stock shot more than 10% higher Friday, with most of those gains coming in the last hour of the session. Shares were largely quiet in after-hours trading, when the announcement was made.
-Jeremy C. Owens; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 29, 2020 17:15 ET (21:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.